Phase 1 Study To Determine The Safety And Dosing Of Autologous Pbmcs Modified To Present Hpv16 Antigens (Sqz-Pbmc-Hpv) In Hla-A*02+ Patients With Hpv16+ Solid Tumors

Jimeno, A., Baranda, J., Iams, J.W., Park, J.C., Mita, M., Gordon, M.S., Taylor, M. Dhani, N., Leal, A.D., Neupane, P. Eng, C., Yeku, O., Mita, A., Moser, J.C., Butler, M., Loughhead, S.M., Jennings, J. Miselis, N.R., Ji, R-R, Nair, N., Kornacker, M., Zwirtes, R.F., Bernstein, H., Sharei, A. Phase 1 Study To Determine The Safety And Dosing Of Autologous Pbmcs Modified To Present Hpv16 Antigens (Sqz-Pbmc-Hpv) In Hla-A*02+ Patients With Hpv16+ Solid Tumors. Investigational New Drugs, 2023. May-23.